151 related articles for article (PubMed ID: 37933521)
21. Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study: Brexpiprazole d'appoint pour l'engagement dans la vie des patients souffrant de trouble dépressif majeur: une étude interventionnelle canadienne ouverte de phase 4.
Therrien F; Ward C; Chokka P; Habert J; Ismail Z; McIntyre RS; MacKenzie EM
Can J Psychiatry; 2024 Jul; 69(7):513-523. PubMed ID: 38425284
[TBL] [Abstract][Full Text] [Related]
22. Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis.
Kishi T; Sakuma K; Nomura I; Matsuda Y; Mishima K; Iwata N
Int J Neuropsychopharmacol; 2019 Nov; 22(11):698-709. PubMed ID: 31350882
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
[TBL] [Abstract][Full Text] [Related]
24. Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open-label, long-term safety and tolerability study.
Lepola U; Hefting N; Zhang D; Hobart M
Int J Geriatr Psychiatry; 2018 Oct; 33(10):1403-1410. PubMed ID: 30039634
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study.
Ozaki N; Otsubo T; Kato M; Higuchi T; Ono H; Kamijima K;
Psychiatry Clin Neurosci; 2015 Jan; 69(1):34-42. PubMed ID: 24965202
[TBL] [Abstract][Full Text] [Related]
26. Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
Earley WR; Guo H; Németh G; Harsányi J; Thase ME
Psychopharmacol Bull; 2018 Jun; 48(4):62-80. PubMed ID: 30618475
[TBL] [Abstract][Full Text] [Related]
27. Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study).
Kamijima K; Higuchi T; Ishigooka J; Ohmori T; Ozaki N; Kanba S; Kinoshita T; Koyama T;
J Affect Disord; 2013 Dec; 151(3):899-905. PubMed ID: 24074484
[TBL] [Abstract][Full Text] [Related]
28. Changes in Metabolic Parameters and Body Weight in Patients With Major Depressive Disorder Treated With Adjunctive Brexpiprazole: Pooled Analysis of Phase 3 Clinical Studies.
Newcomer JW; Eriksson H; Zhang P; Meehan SR; Weiss C
J Clin Psychiatry; 2019 Oct; 80(6):. PubMed ID: 31577867
[TBL] [Abstract][Full Text] [Related]
29. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
[TBL] [Abstract][Full Text] [Related]
30. Adjunctive Brexpiprazole as a Novel Effective Strategy for Treating Major Depressive Disorder: A Systematic Review and Meta-Analysis.
Yoon S; Jeon SW; Ko YH; Patkar AA; Masand PS; Pae CU; Han C
J Clin Psychopharmacol; 2017 Feb; 37(1):46-53. PubMed ID: 27941419
[TBL] [Abstract][Full Text] [Related]
31. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
Inoue T; Sasai K; Kitagawa T; Nishimura A; Inada I
Psychiatry Clin Neurosci; 2020 Feb; 74(2):140-148. PubMed ID: 31725942
[TBL] [Abstract][Full Text] [Related]
32. Effects of Adjunctive Brexpiprazole on Sleep Disturbances in Patients With Major Depressive Disorder: An Open-Label, Flexible-Dose, Exploratory Study.
Krystal AD; Mittoux A; Meisels P; Baker RA
Prim Care Companion CNS Disord; 2016 Sep; 18(5):. PubMed ID: 27835722
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.
Nelson JC; Rahman Z; Laubmeier KK; Eudicone JM; McQuade RD; Berman RM; Marcus RN; Baker RA; Sheehan JJ
CNS Spectr; 2014 Dec; 19(6):528-34. PubMed ID: 24642260
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder.
Durgam S; Earley W; Guo H; Li D; Németh G; Laszlovszky I; Fava M; Montgomery SA
J Clin Psychiatry; 2016 Mar; 77(3):371-8. PubMed ID: 27046309
[TBL] [Abstract][Full Text] [Related]
35. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
[TBL] [Abstract][Full Text] [Related]
36. Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis.
Stewart TD; Hatch A; Largay K; Sheehan JJ; Marler SV; Berman RM; Nelson JC
J Affect Disord; 2014 Jun; 162():20-5. PubMed ID: 24766999
[TBL] [Abstract][Full Text] [Related]
37. Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies.
Fava M; Thase ME; Trivedi MH; Ehrich E; Martin WF; Memisoglu A; Nangia N; Stanford AD; Yu M; Pathak S
Mol Psychiatry; 2020 Jul; 25(7):1580-1591. PubMed ID: 30374191
[TBL] [Abstract][Full Text] [Related]
38. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
[TBL] [Abstract][Full Text] [Related]
39. Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study.
Sanacora G; Johnson MR; Khan A; Atkinson SD; Riesenberg RR; Schronen JP; Burke MA; Zajecka JM; Barra L; Su HL; Posener JA; Bui KH; Quirk MC; Piser TM; Mathew SJ; Pathak S
Neuropsychopharmacology; 2017 Mar; 42(4):844-853. PubMed ID: 27681442
[TBL] [Abstract][Full Text] [Related]
40. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
